Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
MDM2
Name:
MDM2 proto-oncogene
Location:
12q15
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT01280448 | The Correlation Between Lung Cancer Susceptibility Drug Response and Genetic Polymorphism | View | |
| NCT02343172 | Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | View | |
| NCT02407080 | Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia | View | |
| NCT05455658 | STEMVAC in Patients With Early Stage Triple Negative Breast Cancer | View | |
| NCT04275518 | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS | View | |
| NCT06370871 | Brightline-3 A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma | View | |
| NCT01692496 | Activity and Tolerability of Pazopanib in Advanced andor Metastatic Liposarcoma A Phase II Clinical Trial | View | |
| NCT01462175 | A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia | View | |
| NCT01677780 | An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies | View | |
| NCT04669067 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | View | |
| NCT04113616 | An Open-Label Multicenter Phase 1b2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine LDAC or Decitabine in Patients With Acute Myeloid Leukemia AML | View | |
| NCT01605526 | A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma | View | |
| NCT04979442 | Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma | View | |
| NCT04190550 | Testing the Addition of an Anti-cancer Drug Navtemadlin to the Usual Treatments Cytarabine and Idarubicin in Patients With Acute Myeloid Leukemia | View | |
| NCT01664000 | A Safety Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors | View | |
| NCT05155709 | A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia AML Who Are Ineligible for Chemotherapy | View | |
| NCT02098967 | A Study of the Safety and Pharmacokinetics of RO6839921 An MDM2 Antagonist in Patients With Advanced Cancers Including Acute Myeloid Leukemia | View | |
| NCT02143635 | Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt | View | |
| NCT05447663 | A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant | View | |
| NCT05512377 | Brightline-2 A Study to Test Whether Brigimadlin BI 907828 Helps People With Cancer in the Biliary Tract Pancreas Lung or Bladder | View | |
| NCT05613036 | A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body | View | |
| NCT03566485 | Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer | View | |
| NCT02545283 | A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia AML | View | |
| NCT06058793 | Brightline-4 A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma | View | |
| NCT04640532 | KRT-232 in Combination With TL-895 for the Treatment of RR MF and KRT-232 for the Treatment of JAKi Intolerant MF | View | |
| NCT03449381 | This Study Aims to Find the Best Dose of BI 907828 Brigimadlin in Patients With Different Types of Advanced Cancer Solid Tumors | View | |
| NCT03654716 | Phase 1 Study of the Dual MDM2MDMX Inhibitor ALRN-6924 in Pediatric Cancer | View | |
| NCT03669965 | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera | View | |
| NCT03671564 | Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia AML | View | |
| NCT03714958 | Trametinib HDM201 in CRC Patients With RASRAF Mutant and TP53 Wild-type AdvancedMetastatic Colorectal Cancer Mutant and TP53 Wild-type | View | |
| NCT03781986 | APG-115 in Salivary Gland Cancer Trial | View | |
| NCT06578624 | Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors | View | |
| NCT04224064 | Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas | View | |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With RR DLBCL or RR CLL | View | |
| NCT05952687 | Trial of Idasanutlin and Selinexor Therapy for Children With ProgressiveRelapsed ATRT or Extra-CNS Malignant Rhabdoid Tumors | View | |
| NCT04835584 | KRT-232 and TKI Study in Chronic Myeloid Leukemia | View | |
| NCT03031730 | Testing the Addition of KRT-232 AMG 232 to Usual Chemotherapy for Relapsed Multiple Myeloma | View | |
| NCT05012397 | Milademetan in AdvancedMetastatic Solid Tumors | View | |
| NCT05027867 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | View | |
| NCT05218499 | Brightline-1 A Study to Compare Brigimadlin BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | View | |
| NCT02579824 | Ascending Dose and Exploratory Expansion Study of DS-3032b an Oral MDM2 Inhibitor in Subjects With Relapsed andor Refractory Multiple Myeloma | View | |
| NCT06619509 | A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine | View | |
| NCT05775406 | Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies Acute Lymphocytic Leukemia Lymphoma Solid Tumors | View | |
| NCT06414434 | BTX-A51 in Patients with Liposarcoma | View | |
| NCT05242965 | A Multiple Antigen Vaccine STEMVAC for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer | View | |
| NCT03787602 | Navtemadlin KRT-232 With or Without Anti-PD-1Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | View | |
| NCT05372367 | A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor | View | |
| NCT05376800 | A Study to Determine How BI 907828 Brigimadlin is Taken up in the Tumor Phase 0 and to Determine the Highest Dose of BI 907828 Brigimadlin That Could be Tolerated Phase 1a in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma | View | |
| NCT02319369 | Safety Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine AZA in Acute Myelogenous Leukemia AML or High-Risk Myelodysplastic Syndrome MDS | View | |
| NCT02935907 | APG-115 in Patients With Advanced Solid Tumors or Lymphomas | View | |
| NCT03362723 | A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors | View | |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | View | |
| NCT03634228 | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia | View | |
| NCT03662126 | KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment | View | |
| NCT03964233 | A Study in Patients With Different Types of Advanced Cancer Solid Tumors to Test Different Doses of BI 907828 Brigimadlin in Combination With BI 754091 Ezabenlimab and BI 754111 or BI 907828 Brigimadlin in Combination With BI 754091 Ezabenlimab | View |